RCEL

AVITA Medical, Inc. (RCEL) - 10-Q Summary for Period Ended June 30, 2026

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. AVITA Medical is a therapeutic acute wound care company focused on the RECELL platform (autologous skin cell suspension), Cohealyx (collagen-based dermal matrix), and PermeaDerm (biosynthetic wound matrix). The company operates as a single reporting segment with a primary focus on U.S. burn and trauma centers, alongside international distribution partnerships.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 18% year-over-year (Q2) and 11% year-over-year (YTD). Growth was driven by Cohealyx adoption, RECELL GO mini utilization, and normalized RECELL usage following the resolution of Medicare Administrative Contractor (MAC) reimbursement delays.
• Expense Reduction: Total operating expenses decreased 6% in Q2 and 8% YTD compared to the prior year periods. This was achieved through reduced sales commissions, lower marketing spend, and decreased stock-based compensation.
• Debt Refinancing: In January 2026, the company entered a new $60 million credit facility with Perceptive Advisors, drawing $50 million to repay the previous credit agreement. This resulted in net proceeds of approximately $6.0 million.
• Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for the next 12 months due to recurring losses, negative cash flows, and debt obligations. Consequently, the long-term portion of the credit facility is classified as a current liability.

Guidance, Outlook, and Risks

• Outlook: The company aims to achieve long-term operating profitability by driving commercial revenue growth and improving operating leverage. Strategic objectives include expanding RECELL GO mini adoption and repositioning PermeaDerm as an allograft alternative.
• Regulatory Developments: CMS released proposed rules for 2027 Medicare payment for RECELL procedures, which could transition reimbursement to a national fee schedule, potentially improving transparency and utilization.
• Key Risks:
  • Liquidity: The company requires additional funding to sustain operations over the next 12 months. There is no assurance that equity or debt financing will be available on favorable terms.
  • Debt Covenants: The new credit facility includes financial maintenance tests requiring minimum trailing twelve-month net revenue (e.g., $69.0 million for the quarter ended June 30, 2026) and a minimum cash balance of $5.0 million.
  • Contractual Obligations: A $3.0 million contingent payment to Regenity Biosciences is due by January 4, 2027, contingent on clinical study results.

Investor Verification Checklist

• Covenant Compliance: Verify the company's ability to meet the $69.0 million trailing twelve-month revenue covenant for the quarter ended June 30, 2026, and the $5.0 million minimum cash balance requirement.
• Liquidity Runway: Assess the sufficiency of current cash ($9.1M) and marketable securities ($2.0M) against operating burn rates and upcoming debt service obligations.
• Regulatory Milestones: Monitor the finalization of the 2027 CMS Medicare Physician Fee Schedule rules and their impact on RECELL reimbursement rates.
• Contingent Liabilities: Track the status of the Cohealyx clinical studies determining the $3.0 million payment obligation to Regenity due in early 2027.
• Product Mix Impact: Analyze the gross margin impact of the revenue-sharing agreements for Cohealyx (50% split) and PermeaDerm (60% split) as these products scale.